• By Concept
  • By Last Name
  • By Full Text

Bin Tean Teh

Publication Detail

The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.



Renal cell carcinoma deep sequencing: recent developments.

Leslie J Farber; Kyle Furge; Bin Tean Teh (Profiled Authors: Bin Tean Teh; Kyle A Furge)

ljfarber@gmail.com
Current oncology reports 2012;14(3):240-8.

Abstract

Renal cell carcinoma (RCC) is the most common type of renal cancer in adults. RCC is notoriously resistant to current therapies suggesting the need to improve our knowledge and create more effective therapies. The molecular genetic defects that occur in RCC are extensive and complex ranging from single DNA changes, to large chromosomal defects, to signature disruptions in the transcription of hundreds of genes. These changes are often shared within each histological RCC subtype, illustrating their significance to the disease phenotype. This review presents an overview of the genetic abnormalities that occur within the most common subtypes of RCC. We discuss the recent molecular findings that have advanced our understanding of the somatic architecture of renal tumors and their impact on disease therapeutics.

Scientific Context

This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.

Related Grants

  • 1.

    VALDIVIESO, MANUEL

    SOUTHWEST ONCOLOGY GROUP

    1 January 1978 - 31 December 1997

    NATIONAL CANCER INSTITUTE

    Total Funding: $ 1,095,436

Related Publications